Review



genome wide dna methylation microarray data  (Illumina Inc)


Bioz Verified Symbol Illumina Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Illumina Inc genome wide dna methylation microarray data
    In this study, genome-wide <t>DNA</t> <t>methylation</t> of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.
    Genome Wide Dna Methylation Microarray Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 97/100, based on 1703 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+microarray+data/iScan+System/bio_rxiv__2024__12__02__626017-43-0-14
    Average 97 stars, based on 1703 article reviews
    genome wide dna methylation microarray data - by Bioz Stars, 2026-09
    97/100 stars

    Images

    1) Product Images from "Epigenetic investigation of multifocal small intestinal neuroendocrine tumours reveals accelerated ageing of tumours and epigenetic alteration of metabolic genes"

    Article Title: Epigenetic investigation of multifocal small intestinal neuroendocrine tumours reveals accelerated ageing of tumours and epigenetic alteration of metabolic genes

    Journal: bioRxiv

    doi: 10.1101/2024.12.02.626017

    In this study, genome-wide DNA methylation of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.
    Figure Legend Snippet: In this study, genome-wide DNA methylation of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.

    Techniques Used: Genome Wide, DNA Methylation Assay, Methylation

    (A) Plot of age predictions for normal epithelia samples (green), primary tumours (purple) and metastatic tumours (blue). Chronological age is indicated with the orange points and patients are indicated in order of chronological age. (B) Boxplot of age acceleration difference for the skin and blood clock predictions. (C) Somatic mutation count from tumours correlates with DNA methylation age in the skin and blood clock (p=0.0007).
    Figure Legend Snippet: (A) Plot of age predictions for normal epithelia samples (green), primary tumours (purple) and metastatic tumours (blue). Chronological age is indicated with the orange points and patients are indicated in order of chronological age. (B) Boxplot of age acceleration difference for the skin and blood clock predictions. (C) Somatic mutation count from tumours correlates with DNA methylation age in the skin and blood clock (p=0.0007).

    Techniques Used: Mutagenesis, DNA Methylation Assay

    Related Articles

    other:

    Article Title: Super Partition: fast, flexible, and interpretable large-scale data reduction in R
    Article Snippet: The computational efficiency of Super Partition was assessed and compared to Partition in several datasets, including transcriptome-wide microarray data in whole blood from the ABRIDGE and CAMP asthma cohorts ( n = 865, number of features (f) = 19,428) ( ; ), transcriptome-wide RNA-seq data in colon adenocarcinoma tumor tissue from The Cancer Genome Atlas (TCGA) ( n = 481, f = 60,660) , and Illumina 450K DNA methylation (DNAm) array data from the ABRIDGE cohort.

    Article Title: Directional integration and pathway enrichment analysis for multi-omics data
    Article Snippet: To validate our pathway enrichment analysis of IDH1 -mutant gliomas from TCGA and CPTAC, we repeated the analysis in independent glioma samples using transcriptomics (RNA-seq), quantitative proteomics (isobaric label quantitation analysis with orbitrap), and DNA methylation data (CpG Illumina 450k microarray).

    DNA Methylation Assay:

    Article Title: Robust molecular subgrouping and reference-free aneuploidy detection in medulloblastoma using low-depth whole genome bisulfite sequencing.
    Article Snippet: .. This classifier relies on data arising from Illumina DNA methylation microarray technology, a cost-effective assay whose current release interrogates ~ 935,000 CpGs across the human genome and is compatible with both fresh-frozen and FFPE DNA derivatives [15]. ..

    Article Title: Measuring technical variability in illumina DNA methylation microarrays.
    Article Snippet: .. In this study, we measure the impact of common sources of technical variability in Illumina DNA methylation microarray data, with a specific focus on positional biases inherent within the microarray technology. ..

    Article Title: Epigenetic investigation of multifocal small intestinal neuroendocrine tumours reveals accelerated ageing of tumours and epigenetic alteration of metabolic genes
    Article Snippet: .. Genome-wide DNA methylation microarray data was generated on the Illumina iScan System using the Illumina Infinium MethylationEPIC BeadChip according to the manufacturer’s protocol. ..

    Article Title: Robust molecular subgrouping and reference-free aneuploidy detection in medulloblastoma using low-depth whole genome bisulfite sequencing
    Article Snippet: .. This classifier relies on data arising from Illumina DNA methylation microarray technology, a cost-effective assay whose current release interrogates ~ 935,000 CpGs across the human genome and is compatible with both fresh-frozen and FFPE DNA derivatives [ ]. ..

    Article Title: Exploring the potential biological significance of KDELR family genes in lung adenocarcinoma
    Article Snippet: .. This comprehensive dataset incorporates DNA methylation microarray data, generated using the Illumina HumanMethylation450 platform, encompassing over 10,000 samples across 34 distinct cancer types . ..

    Article Title: Developmentally dynamic changes in DNA methylation in the human pancreas.
    Article Snippet: .. DNA methylation at specific sites was considered to be significantly associated with development (in PCW) and sex if they passed an experiment-wide significance threshold of P = 9 × 10–8 previously determined by our group to adequately control for false positive associations using Illumina EPIC array DNA methylation data [19]. ..

    Microarray:

    Article Title: Robust molecular subgrouping and reference-free aneuploidy detection in medulloblastoma using low-depth whole genome bisulfite sequencing.
    Article Snippet: .. This classifier relies on data arising from Illumina DNA methylation microarray technology, a cost-effective assay whose current release interrogates ~ 935,000 CpGs across the human genome and is compatible with both fresh-frozen and FFPE DNA derivatives [15]. ..

    Article Title: Measuring technical variability in illumina DNA methylation microarrays.
    Article Snippet: .. In this study, we measure the impact of common sources of technical variability in Illumina DNA methylation microarray data, with a specific focus on positional biases inherent within the microarray technology. ..

    Article Title: Epigenetic investigation of multifocal small intestinal neuroendocrine tumours reveals accelerated ageing of tumours and epigenetic alteration of metabolic genes
    Article Snippet: .. Genome-wide DNA methylation microarray data was generated on the Illumina iScan System using the Illumina Infinium MethylationEPIC BeadChip according to the manufacturer’s protocol. ..

    Article Title: Robust molecular subgrouping and reference-free aneuploidy detection in medulloblastoma using low-depth whole genome bisulfite sequencing
    Article Snippet: .. This classifier relies on data arising from Illumina DNA methylation microarray technology, a cost-effective assay whose current release interrogates ~ 935,000 CpGs across the human genome and is compatible with both fresh-frozen and FFPE DNA derivatives [ ]. ..

    Article Title: Exploring the potential biological significance of KDELR family genes in lung adenocarcinoma
    Article Snippet: .. This comprehensive dataset incorporates DNA methylation microarray data, generated using the Illumina HumanMethylation450 platform, encompassing over 10,000 samples across 34 distinct cancer types . ..

    Formalin-fixed Paraffin-Embedded:

    Article Title: Robust molecular subgrouping and reference-free aneuploidy detection in medulloblastoma using low-depth whole genome bisulfite sequencing.
    Article Snippet: .. This classifier relies on data arising from Illumina DNA methylation microarray technology, a cost-effective assay whose current release interrogates ~ 935,000 CpGs across the human genome and is compatible with both fresh-frozen and FFPE DNA derivatives [15]. ..

    Article Title: Robust molecular subgrouping and reference-free aneuploidy detection in medulloblastoma using low-depth whole genome bisulfite sequencing
    Article Snippet: .. This classifier relies on data arising from Illumina DNA methylation microarray technology, a cost-effective assay whose current release interrogates ~ 935,000 CpGs across the human genome and is compatible with both fresh-frozen and FFPE DNA derivatives [ ]. ..

    Genome Wide:

    Article Title: Epigenetic investigation of multifocal small intestinal neuroendocrine tumours reveals accelerated ageing of tumours and epigenetic alteration of metabolic genes
    Article Snippet: .. Genome-wide DNA methylation microarray data was generated on the Illumina iScan System using the Illumina Infinium MethylationEPIC BeadChip according to the manufacturer’s protocol. ..

    Generated:

    Article Title: Epigenetic investigation of multifocal small intestinal neuroendocrine tumours reveals accelerated ageing of tumours and epigenetic alteration of metabolic genes
    Article Snippet: .. Genome-wide DNA methylation microarray data was generated on the Illumina iScan System using the Illumina Infinium MethylationEPIC BeadChip according to the manufacturer’s protocol. ..

    Article Title: Exploring the potential biological significance of KDELR family genes in lung adenocarcinoma
    Article Snippet: .. This comprehensive dataset incorporates DNA methylation microarray data, generated using the Illumina HumanMethylation450 platform, encompassing over 10,000 samples across 34 distinct cancer types . ..

    Control:

    Article Title: Developmentally dynamic changes in DNA methylation in the human pancreas.
    Article Snippet: .. DNA methylation at specific sites was considered to be significantly associated with development (in PCW) and sex if they passed an experiment-wide significance threshold of P = 9 × 10–8 previously determined by our group to adequately control for false positive associations using Illumina EPIC array DNA methylation data [19]. ..



    Similar Products

    dna microarray data  (Thermo Fisher)
    99
    Thermo Fisher dna microarray data
    Dna Microarray Data, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+microarray+data/Deoxyribonucleic+acid/pm41194255-146-11-31
    Average 99 stars, based on 1 article reviews
    dna microarray data - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    450k infinium microarray dna methylation data  (INFINIUM Inc)
    90
    INFINIUM Inc 450k infinium microarray dna methylation data
    H1‐0 is consistently upregulated in preleukemia and BCP‐ALL expressing ETV6::RUNX1 . (A) Principal component analysis (PCA) plot of ETV6::RUNX1 + (E::R) and wild‐type (WT) hiPSC transcriptome profiles based on all detected genes ( n = 16,328). (B) Hierarchical clustering analysis of differentially expressed genes (absolute fold change > 2 and p < 0.05) between ETV6::RUNX1 + and WT hiPSCs detected by RNA‐seq. (C) H1‐0 expression levels determined by RT‐qPCR in ETV6::RUNX1 + and WT hiPSCs subjected to RNA‐seq. Values were normalized to HW8 WT expression levels as well as to GAPDH expression. (D) Representative Western blot analysis of ETV6::RUNX1, H1‐0, ETV6, and β‐actin levels in ETV6::RUNX1 + and WT hiPSCs. (E) H1‐0 levels in HSCs (CD19‐CD34+CD45RA‐), IL7R+ (CD19‐CD34+CD45RA+IL7R+), and pro‐B (CD19+CD34+) cells differentiated from ETV6::RUNX1 + or reverted MIFF3 hiPSCs, and fetal liver cells. Data are derived from an RNA‐seq dataset by Böiers et al. (accession number E‐MTAB‐6382 <xref ref-type= 10 ). Data were analyzed for statistical significance using an ordinary one‐way ANOVA (* p < 0.05, ** p < 0.01). H1‐0 levels across two leukemia patient cohorts derived from the (F) PeCan St. Jude database 30 , 31 and (G) an expression microarray dataset (accession number GSE87070 32 ). The number of patients per leukemia entity and mean expression is indicated. Data were analyzed for statistical significance using an ordinary one‐way ANOVA (*** p < 0.001). (H) H1‐0 expression was quantified by RT‐qPCR in PDX samples ( n = 9). Mean expression ± standard deviation is shown. (I) RNA‐seq expression levels of H1‐0 in control and ETV6 shRNA‐transduced REH cells. Data are derived from E‐MTAB‐10308 11 and are normalized to control shRNA. Mean expression ± standard deviation is indicated. Statistical significance was determined by performing a one‐way ANOWA (*** p < 0.001). (J) Pearson correlation of H1‐0 and RUNX1 expression in healthy bone marrow cells ( n = 71) derived from the MILE study (R2 platform, accession number GSE13159 33 ). " width="250" height="auto" />
    450k Infinium Microarray Dna Methylation Data, supplied by INFINIUM Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+microarray+data/infinium+humanmethylation450+beadchip/pmc11962653-118-5-6
    Average 90 stars, based on 1 article reviews
    450k infinium microarray dna methylation data - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    genome wide dna methylation microarray data  (Illumina Inc)
    97
    Illumina Inc genome wide dna methylation microarray data
    In this study, genome-wide <t>DNA</t> <t>methylation</t> of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.
    Genome Wide Dna Methylation Microarray Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+microarray+data/iScan+System/bio_rxiv__2024__12__02__626017-43-0-14
    Average 97 stars, based on 1 article reviews
    genome wide dna methylation microarray data - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    hg u133a dna microarray data  (Thermo Fisher)
    99
    Thermo Fisher hg u133a dna microarray data
    In this study, genome-wide <t>DNA</t> <t>methylation</t> of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.
    Hg U133a Dna Microarray Data, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+microarray+data/DNA/pmc11562011-149-6-5
    Average 99 stars, based on 1 article reviews
    hg u133a dna microarray data - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    whole-genome dna microarray expression data  (Dawley Inc)
    90
    Dawley Inc whole-genome dna microarray expression data
    In this study, genome-wide <t>DNA</t> <t>methylation</t> of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.
    Whole Genome Dna Microarray Expression Data, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+microarray+data/whole+genome+dna+microarray+expression+data/10__37897_slash_rjphp__2024__1___2__3-111-3-14
    Average 90 stars, based on 1 article reviews
    whole-genome dna microarray expression data - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    dna methylation microarray data  (Illumina Inc)
    90
    Illumina Inc dna methylation microarray data
    In this study, genome-wide <t>DNA</t> <t>methylation</t> of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.
    Dna Methylation Microarray Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+microarray+data/dna+methylation+arrays/pmc11211404-229-4-11
    Average 90 stars, based on 1 article reviews
    dna methylation microarray data - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    affymetrix dna microarray data  (Thermo Fisher)
    99
    Thermo Fisher affymetrix dna microarray data
    In this study, genome-wide <t>DNA</t> <t>methylation</t> of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.
    Affymetrix Dna Microarray Data, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+microarray+data/DNA/pm38587783-22-4-4
    Average 99 stars, based on 1 article reviews
    affymetrix dna microarray data - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    high-throughput molecular abundance data, predominantly gene expression data generated by dna microarray  (Biotechnology Information)
    90
    Biotechnology Information high-throughput molecular abundance data, predominantly gene expression data generated by dna microarray
    In this study, genome-wide <t>DNA</t> <t>methylation</t> of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.
    High Throughput Molecular Abundance Data, Predominantly Gene Expression Data Generated By Dna Microarray, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+microarray+data/high+throughput+molecular+abundance+data++predominantly+gene+expression+data+generated+by+dna+microarray/pmc11157084-52-28-11
    Average 90 stars, based on 1 article reviews
    high-throughput molecular abundance data, predominantly gene expression data generated by dna microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    H1‐0 is consistently upregulated in preleukemia and BCP‐ALL expressing ETV6::RUNX1 . (A) Principal component analysis (PCA) plot of ETV6::RUNX1 + (E::R) and wild‐type (WT) hiPSC transcriptome profiles based on all detected genes ( n = 16,328). (B) Hierarchical clustering analysis of differentially expressed genes (absolute fold change > 2 and p < 0.05) between ETV6::RUNX1 + and WT hiPSCs detected by RNA‐seq. (C) H1‐0 expression levels determined by RT‐qPCR in ETV6::RUNX1 + and WT hiPSCs subjected to RNA‐seq. Values were normalized to HW8 WT expression levels as well as to GAPDH expression. (D) Representative Western blot analysis of ETV6::RUNX1, H1‐0, ETV6, and β‐actin levels in ETV6::RUNX1 + and WT hiPSCs. (E) H1‐0 levels in HSCs (CD19‐CD34+CD45RA‐), IL7R+ (CD19‐CD34+CD45RA+IL7R+), and pro‐B (CD19+CD34+) cells differentiated from ETV6::RUNX1 + or reverted MIFF3 hiPSCs, and fetal liver cells. Data are derived from an RNA‐seq dataset by Böiers et al. (accession number E‐MTAB‐6382 <xref ref-type= 10 ). Data were analyzed for statistical significance using an ordinary one‐way ANOVA (* p < 0.05, ** p < 0.01). H1‐0 levels across two leukemia patient cohorts derived from the (F) PeCan St. Jude database 30 , 31 and (G) an expression microarray dataset (accession number GSE87070 32 ). The number of patients per leukemia entity and mean expression is indicated. Data were analyzed for statistical significance using an ordinary one‐way ANOVA (*** p < 0.001). (H) H1‐0 expression was quantified by RT‐qPCR in PDX samples ( n = 9). Mean expression ± standard deviation is shown. (I) RNA‐seq expression levels of H1‐0 in control and ETV6 shRNA‐transduced REH cells. Data are derived from E‐MTAB‐10308 11 and are normalized to control shRNA. Mean expression ± standard deviation is indicated. Statistical significance was determined by performing a one‐way ANOWA (*** p < 0.001). (J) Pearson correlation of H1‐0 and RUNX1 expression in healthy bone marrow cells ( n = 71) derived from the MILE study (R2 platform, accession number GSE13159 33 ). " width="100%" height="100%">

    Journal: HemaSphere

    Article Title: H1‐0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia

    doi: 10.1002/hem3.70116

    Figure Lengend Snippet: H1‐0 is consistently upregulated in preleukemia and BCP‐ALL expressing ETV6::RUNX1 . (A) Principal component analysis (PCA) plot of ETV6::RUNX1 + (E::R) and wild‐type (WT) hiPSC transcriptome profiles based on all detected genes ( n = 16,328). (B) Hierarchical clustering analysis of differentially expressed genes (absolute fold change > 2 and p < 0.05) between ETV6::RUNX1 + and WT hiPSCs detected by RNA‐seq. (C) H1‐0 expression levels determined by RT‐qPCR in ETV6::RUNX1 + and WT hiPSCs subjected to RNA‐seq. Values were normalized to HW8 WT expression levels as well as to GAPDH expression. (D) Representative Western blot analysis of ETV6::RUNX1, H1‐0, ETV6, and β‐actin levels in ETV6::RUNX1 + and WT hiPSCs. (E) H1‐0 levels in HSCs (CD19‐CD34+CD45RA‐), IL7R+ (CD19‐CD34+CD45RA+IL7R+), and pro‐B (CD19+CD34+) cells differentiated from ETV6::RUNX1 + or reverted MIFF3 hiPSCs, and fetal liver cells. Data are derived from an RNA‐seq dataset by Böiers et al. (accession number E‐MTAB‐6382 10 ). Data were analyzed for statistical significance using an ordinary one‐way ANOVA (* p < 0.05, ** p < 0.01). H1‐0 levels across two leukemia patient cohorts derived from the (F) PeCan St. Jude database 30 , 31 and (G) an expression microarray dataset (accession number GSE87070 32 ). The number of patients per leukemia entity and mean expression is indicated. Data were analyzed for statistical significance using an ordinary one‐way ANOVA (*** p < 0.001). (H) H1‐0 expression was quantified by RT‐qPCR in PDX samples ( n = 9). Mean expression ± standard deviation is shown. (I) RNA‐seq expression levels of H1‐0 in control and ETV6 shRNA‐transduced REH cells. Data are derived from E‐MTAB‐10308 11 and are normalized to control shRNA. Mean expression ± standard deviation is indicated. Statistical significance was determined by performing a one‐way ANOWA (*** p < 0.001). (J) Pearson correlation of H1‐0 and RUNX1 expression in healthy bone marrow cells ( n = 71) derived from the MILE study (R2 platform, accession number GSE13159 33 ).

    Article Snippet: Hence, we analyzed previously published 450K Infinium microarray DNA methylation data comprising patient samples of T‐ALL and six B‐ALL subtypes ( n = 546).

    Techniques: Expressing, RNA Sequencing, Quantitative RT-PCR, Western Blot, Derivative Assay, Microarray, Standard Deviation, Control, shRNA

    ETV6::RUNX1 induces H1‐0 promoter activation . (A) Schematic representation of the H1‐0 locus, including the 512‐bp region (nucleotides −351 to +161 from TSS) encompassing promoter‐like signature EH38E2163184 (ENCODE). The H1‐0 CpG island (CGI) shore and 450K Infinium array probes are indicated. (B) 293T cells were transfected with a vector encoding the H1‐0 promoter‐like signature indicated in (A) , together with the empty pcDNA3.1 vector or pcDNA3.1 expressing either ETV6::RUNX1 or RUNX1, and a vector expressing Renilla luciferase. Luciferase activities were normalized to Renilla luciferase activity and the empty vector control. Data represent mean values of three independent replicates ± standard deviation. Significance was calculated using an ordinary one‐way ANOVA (*** p < 0.001). Representative protein levels of ETV6::RUNX1, RUNX1, and β‐actin determined by Western blot are shown. (C) Pearson correlation of H1‐0 expression and mean DNA methylation of the H1‐0 CGI shore probes cg07141002 and cg01883777 in leukemia patients (accession number GSE49032 <xref ref-type= 41 ). Expression is shown for microarray probe 208886_at. Each dot represents a single patient. (D) H1‐0 DNA methylation in different leukemia entities is visualized as a heatmap with each column corresponding to a single patient (accession number GSE49032 41 ). Within each entity, patients are sorted according to mean DNA methylation of CGI shore probes cg07141002 and cg01883777. The total number of patients per entity is indicated. " width="100%" height="100%">

    Journal: HemaSphere

    Article Title: H1‐0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia

    doi: 10.1002/hem3.70116

    Figure Lengend Snippet: ETV6::RUNX1 induces H1‐0 promoter activation . (A) Schematic representation of the H1‐0 locus, including the 512‐bp region (nucleotides −351 to +161 from TSS) encompassing promoter‐like signature EH38E2163184 (ENCODE). The H1‐0 CpG island (CGI) shore and 450K Infinium array probes are indicated. (B) 293T cells were transfected with a vector encoding the H1‐0 promoter‐like signature indicated in (A) , together with the empty pcDNA3.1 vector or pcDNA3.1 expressing either ETV6::RUNX1 or RUNX1, and a vector expressing Renilla luciferase. Luciferase activities were normalized to Renilla luciferase activity and the empty vector control. Data represent mean values of three independent replicates ± standard deviation. Significance was calculated using an ordinary one‐way ANOVA (*** p < 0.001). Representative protein levels of ETV6::RUNX1, RUNX1, and β‐actin determined by Western blot are shown. (C) Pearson correlation of H1‐0 expression and mean DNA methylation of the H1‐0 CGI shore probes cg07141002 and cg01883777 in leukemia patients (accession number GSE49032 41 ). Expression is shown for microarray probe 208886_at. Each dot represents a single patient. (D) H1‐0 DNA methylation in different leukemia entities is visualized as a heatmap with each column corresponding to a single patient (accession number GSE49032 41 ). Within each entity, patients are sorted according to mean DNA methylation of CGI shore probes cg07141002 and cg01883777. The total number of patients per entity is indicated.

    Article Snippet: Hence, we analyzed previously published 450K Infinium microarray DNA methylation data comprising patient samples of T‐ALL and six B‐ALL subtypes ( n = 546).

    Techniques: Activation Assay, Transfection, Plasmid Preparation, Expressing, Luciferase, Activity Assay, Control, Standard Deviation, Western Blot, DNA Methylation Assay, Microarray

    H1‐0 expression decreases during hematopoiesis . (A) H1‐0 expression in ETV6::RUNX1 + BCP‐ALL ( n = 6) and healthy B cell precursor stages derived from a published RNA‐seq dataset (accession number GSE115656 <xref ref-type= 45 ). B cell precursor fractions are HSCs (CD34+CD19‐IgM‐), pro‐B cells (CD34+CD19+IgM‐), pre‐B cells (CD34‐CD19+IgM‐) and immature B cells (CD34‐CD19+IgM+). (B) H1‐0 expression in healthy B cell precursor stages derived from a published expression microarray dataset (accession number GSE24759 46 ). B cell precursor fractions are HSCs (CD34+CD38‐), pro‐B cells (CD34+CD10+CD19+), pre‐B cells (CD34‐CD10+CD19+), naïve B cells (CD19+IgD+CD27‐), and mature B cells (CD19+IgD+CD27+). (B, C) Mean expression ± standard deviation is indicated and data was analyzed for statistical significance using an ordinary one‐way ANOVA (* p < 0.05, *** p < 0.001). (C) Min–max‐normalized mean expression per cell type derived from a fetal liver scRNA‐seq dataset (accession number E‐MTAB‐7407 47 ). (D) H1‐0 expression levels across normal B‐lymphoid differentiation distinguishing cell cycle status is depicted in a scRNA‐seq UMAP visualization of B cell precursor cells from bone marrow of eight healthy donors. 48 " width="100%" height="100%">

    Journal: HemaSphere

    Article Title: H1‐0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia

    doi: 10.1002/hem3.70116

    Figure Lengend Snippet: H1‐0 expression decreases during hematopoiesis . (A) H1‐0 expression in ETV6::RUNX1 + BCP‐ALL ( n = 6) and healthy B cell precursor stages derived from a published RNA‐seq dataset (accession number GSE115656 45 ). B cell precursor fractions are HSCs (CD34+CD19‐IgM‐), pro‐B cells (CD34+CD19+IgM‐), pre‐B cells (CD34‐CD19+IgM‐) and immature B cells (CD34‐CD19+IgM+). (B) H1‐0 expression in healthy B cell precursor stages derived from a published expression microarray dataset (accession number GSE24759 46 ). B cell precursor fractions are HSCs (CD34+CD38‐), pro‐B cells (CD34+CD10+CD19+), pre‐B cells (CD34‐CD10+CD19+), naïve B cells (CD19+IgD+CD27‐), and mature B cells (CD19+IgD+CD27+). (B, C) Mean expression ± standard deviation is indicated and data was analyzed for statistical significance using an ordinary one‐way ANOVA (* p < 0.05, *** p < 0.001). (C) Min–max‐normalized mean expression per cell type derived from a fetal liver scRNA‐seq dataset (accession number E‐MTAB‐7407 47 ). (D) H1‐0 expression levels across normal B‐lymphoid differentiation distinguishing cell cycle status is depicted in a scRNA‐seq UMAP visualization of B cell precursor cells from bone marrow of eight healthy donors. 48

    Article Snippet: Hence, we analyzed previously published 450K Infinium microarray DNA methylation data comprising patient samples of T‐ALL and six B‐ALL subtypes ( n = 546).

    Techniques: Expressing, Derivative Assay, RNA Sequencing, Microarray, Standard Deviation

    In this study, genome-wide DNA methylation of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.

    Journal: bioRxiv

    Article Title: Epigenetic investigation of multifocal small intestinal neuroendocrine tumours reveals accelerated ageing of tumours and epigenetic alteration of metabolic genes

    doi: 10.1101/2024.12.02.626017

    Figure Lengend Snippet: In this study, genome-wide DNA methylation of 100 samples from 11 patients was assessed. Each patient had multiple primary small intestinal neuroendocrine tumours (ranging from 2-16 per patient), and a subset of 9 patients had a matched normal small intestinal epithelial sample assessed. A subset of 8 patients also had metastases originating from their SI-NETs (ranging from 1-2 per patient). DNA methylation data was used to assess differential methylation relating to the multifocal tumours, the epigenetic clock was used to assess the ‘timing’ of tumour development and metabolic traits predicted by DNA methylation were compared between samples.

    Article Snippet: Genome-wide DNA methylation microarray data was generated on the Illumina iScan System using the Illumina Infinium MethylationEPIC BeadChip according to the manufacturer’s protocol.

    Techniques: Genome Wide, DNA Methylation Assay, Methylation

    (A) Plot of age predictions for normal epithelia samples (green), primary tumours (purple) and metastatic tumours (blue). Chronological age is indicated with the orange points and patients are indicated in order of chronological age. (B) Boxplot of age acceleration difference for the skin and blood clock predictions. (C) Somatic mutation count from tumours correlates with DNA methylation age in the skin and blood clock (p=0.0007).

    Journal: bioRxiv

    Article Title: Epigenetic investigation of multifocal small intestinal neuroendocrine tumours reveals accelerated ageing of tumours and epigenetic alteration of metabolic genes

    doi: 10.1101/2024.12.02.626017

    Figure Lengend Snippet: (A) Plot of age predictions for normal epithelia samples (green), primary tumours (purple) and metastatic tumours (blue). Chronological age is indicated with the orange points and patients are indicated in order of chronological age. (B) Boxplot of age acceleration difference for the skin and blood clock predictions. (C) Somatic mutation count from tumours correlates with DNA methylation age in the skin and blood clock (p=0.0007).

    Article Snippet: Genome-wide DNA methylation microarray data was generated on the Illumina iScan System using the Illumina Infinium MethylationEPIC BeadChip according to the manufacturer’s protocol.

    Techniques: Mutagenesis, DNA Methylation Assay